In this video, Diana V. Do, MD, of Byers Eye Institute at Stanford University, discussed with Healio the results from the PANORAMA study presented at the virtual American Academy of Ophthalmology annual meeting.
Eylea (aflibercept, Regeneron) in moderately severe to severe proliferative disease proved safe and effectively improved retinopathy while decreasing vision-threatening complications.
“In my clinical practice, I've started using VEGF inhibitors such as aflibercept for the treatment of non-proliferative diabetic retinopathy. They'll be an emerging area for retina specialists to
Uncategorized